• No results found

Myeloproliferative disease

BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease

BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease

... Translocation (9;22)(q34;q11.2) resulting in BCR/ABL1 fusion at the molecular level is the hallmark of chronic myelogenous leukemia (CML). Variants of the Philadelphia translocation and complex translocations involving ...

6

Conditional expression of oncogenic K ras from its endogenous promoter induces a myeloproliferative disease

Conditional expression of oncogenic K ras from its endogenous promoter induces a myeloproliferative disease

... the myeloproliferative dis- eases induced in murine bone marrow transplant assays by tyrosine kinase fusions such as BCR-ABL, TEL-PDGFRβ, TEL-TRKC, and TEL-JAK2 (17, 41, 45, ...marked myeloproliferative ...

12

PML RARA can increase hematopoietic self renewal without causing a myeloproliferative disease in mice

PML RARA can increase hematopoietic self renewal without causing a myeloproliferative disease in mice

... Acute promyelocytic leukemia (APL) is characterized by the t(15;17) translocation that generates the fusion protein promyelocytic leukemia–retinoic acid receptor a (PML-RARA) in nearly all cases. Multiple prior mouse ...

11

Normal hematopoiesis and neurofibromin deficient myeloproliferative disease require Erk

Normal hematopoiesis and neurofibromin deficient myeloproliferative disease require Erk

... Neurofibromatosis type 1 (NF1) predisposes individuals to the development of juvenile myelomonocytic leu- kemia (JMML), a fatal myeloproliferative disease (MPD). In genetically engineered murine models, ...

7

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice

... Children with neurofibromatosis type 1 (NF1) are predisposed to juvenile myelomonocytic leukemia (JMML), an aggressive myeloproliferative neoplasm (MPN) that is refractory to conventional chemotherapy. Condi- ...

6

A retrovirus carrying the polyomavirus middle T gene induces acute thrombocythemic myeloproliferative disease in mice.

A retrovirus carrying the polyomavirus middle T gene induces acute thrombocythemic myeloproliferative disease in mice.

... Here we describe how inoculation of an artificially constructed retrovirus, the polyomamurine leukemia virus PyMLV, carrying the polyomavirus middle T gene 3, into NIH/OLAC adult mice re[r] ...

5

Platelet Fc Receptor: INCREASED EXPRESSION IN MYELOPROLIFERATIVE DISEASE

Platelet Fc Receptor: INCREASED EXPRESSION IN MYELOPROLIFERATIVE DISEASE

... or myeloproliferative donors did not stain with the immune complexes when the incubation was performed in ...on myeloproliferative platelets was corroborated by studies of [ 14 C]serotonin release by immune ...

9

Pathogenesis and Mutations of Myeloproliferative Neoplasms: An Overview

Pathogenesis and Mutations of Myeloproliferative Neoplasms: An Overview

... Lymphocyte specific adaptor protein (LNK) is a JAK-STAT inhibitor adaptor protein. It is considered that LNK plays a role in the pathogenesis of myeloproliferative diseases. It consists of three regions including ...

24

The Role of MicroRNAs in Myeloproliferative Neoplasia

The Role of MicroRNAs in Myeloproliferative Neoplasia

... clonal myeloproliferative disease related to HSCs, clinically recognized by triple-phase clinical presentation as well as translocation between chromosome 9 and 22 (Philadelphia ...the disease is ...

14

Transient suppression of clonal hemopoiesis associated with pregnancy in a patient with a myeloproliferative disorder

Transient suppression of clonal hemopoiesis associated with pregnancy in a patient with a myeloproliferative disorder

... myeloproliferative disease, and persistence of the abnormal clone throughout the period of study. Analysis of DNA from her blood granulocytes showed these to be polyclonal at mid- pregnancy, when her ...

6

The JAK2V617F Mutation Seen in Myeloproliferative Neoplasms (MPNs) Occurs in Patients with Inflammatory Bowel Disease: Implications of a Pilot Study

The JAK2V617F Mutation Seen in Myeloproliferative Neoplasms (MPNs) Occurs in Patients with Inflammatory Bowel Disease: Implications of a Pilot Study

... Since several JAK2 inhibitors are now available and show efficacy in treating both JAK2 mutated and non-mutated MPNs [23,24], the finding of a higher than expected JAK2 mutation rate in IBDs poses the thera- peutic ...

6

Granulopoiesis in Chronic Myeloproliferative Disorders in Children

Granulopoiesis in Chronic Myeloproliferative Disorders in Children

... §These compare with colony counts of 0 to 6 colonies (mean, 2.6) per 5 x 10 nucleated cells plated from the peripheral blood of ten normal children (ages, 4 to 16 years) studied in Dr.. [r] ...

7

Neurological Complications of Myeloproliferative Syndromes with Negative Philadelphia Chromosome (MPS Ph-) in Lome Tertiary Hospital

Neurological Complications of Myeloproliferative Syndromes with Negative Philadelphia Chromosome (MPS Ph-) in Lome Tertiary Hospital

... On epidemiological aspects, the study found that 76.9% of patients with MPSs Ph negative had neurological complications. Of the patients with ET, eight had neurological complications, which accounted for 66.7%. The ...

5

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms

... and defined under the MDS/MPN-U umbrella diagnosis. This disease has now been accepted as a separate entity in 2016 revision of WHO classification [2]. Splicing fac- tor mutations are common in this group, with ...

7

Targeting the CALR interactome in myeloproliferative neoplasms

Targeting the CALR interactome in myeloproliferative neoplasms

... Stem cell transplantation is currently the only definitive treatment for MF; however, attendant toxicities and advanced age of MF patients preclude the use of transplantation for most patients. Thus, there remains a ...

14

Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada

Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada

... for myeloproliferative neoplasms in Calgary and standardized rate for Canada, which has a proportionally older population, are gener- ally lower than corresponding values from other regions including the United ...

5

Pulmonary hypertension in patients with chronic myeloproliferative disorders

Pulmonary hypertension in patients with chronic myeloproliferative disorders

... their disease, the extent of their disease or their comorbidities, medical therapy including diuretics, anticoagulants and specific PAH therapy should be ...severe disease) with inoperable CTEPH (or ...

11

The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia

The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia

... Myeloproliferative neoplasm (MPN) was distinguished by Polycythaemia Vera Study Group and World Health Organization (WHO) classification as philadelphia (Ph1) chromosome negative essential thrombocythae- mia (ET), ...

12

Molecular Defects in Chronic Myeloproliferative Disorders

Molecular Defects in Chronic Myeloproliferative Disorders

... this disease, including t(8;16)(p11;p13), ...in myeloproliferative dis- orders) on chromosome 13, FGFRI oncogene partner (FOP) on chromosome 6, and mono- cytic leukemia zinc finger (MOZ) on chromo- some ...

13

Low-dose methotrexate in myeloproliferative neoplasm models

Low-dose methotrexate in myeloproliferative neoplasm models

... demonstrated significant hematological and symptomatic improvements in two Italian MPN patients following low-dose MTX treatment. 16 In the light of these results, we suggest that clinical trials should be undertaken to ...

25

Show all 10000 documents...

Related subjects